Clostridium difficile bacteria, computer illustration. C. difficile is a normal inhabitant of the human intestine, but it can become a pathogen when antibiotics disrupt the normal intestinal flora and ...

An experimental antibiotic called EVG7 has shown promise against gram-positive bacterium Clostridioides difficile. | Drug Discovery And Development ...

Vowst restores gut microbiome balance using live biotherapeutic products, differing from traditional antibiotic treatments for C. difficile infections. Clinical trials showed Vowst significantly ...

The panelist discusses how recurrent Clostridioides difficile infections involve complex differential diagnosis, including persistent infection, reinfection, and other gastrointestinal conditions.

Affecting roughly half a million Americans each year, bacterial infections caused by Clostridioides difficile—commonly known as C. diff—are a serious and persistent problem for patients and hospitals ...

A person’s biology may play more of a role in how Clostridioides difficile, or C. diff, spreads more so than healthcare facility preventive measures, a new study finds. This means that transmission of ...

A recent Centers for Disease Control and Prevention report found 75 percent of patients in a group of 10,342 cases were already colonized with C. difficile at the time of hospital admission, according ...

A newly developed antibiotic called EVG7 could offer a powerful new way to stop Clostridioides difficile, a dangerous gut bacterium that often returns after treatment. In mouse studies, researchers ...

Researchers at Tufts University School of Medicine are studying C. diff at multiple levels, from how individual bacterial cells behave inside the gut to the molecular switches that help them survive ...

Nearly half a million people in the United States suffer from an intestinal infection called Clostridium difficile each year. Approximately half of those individuals become sick enough to require ...

STATEN ISLAND, N.Y., Dec. 9, 2024 /PRNewswire/ -- Acurx Pharmaceuticals, Inc. (NASDAQ: ACXP) ("Acurx" or the "Company"), a late-stage biopharmaceutical company developing a new class of small molecule ...

Researchers discovered that men with a history of C. difficile — one of the most common hospital-acquired infections — had lower rates of prostate cancer. The study, published Jan. 30 in Cureus, ...